Your AI-Trained Oncology Knowledge Connection!
A recent study examined the influence of social interactions between cancer patients during chemotherapy sessions, finding that patients who spent time with other patients who died within 5 years had an increased risk of dying within 5 years themselves. Pardon me for being underwhelmed.
This video examines patient fears and misconceptions regarding radiation therapy for the treatment of breast cancer.
When presented with different options, patients perceived physicians that communicated face to face without the use of a computer as being more compassionate, professional, and as having better communication skills.
This video reviews results of a randomized trial comparing intensity modulated radiation therapy vs passively scattered proton therapy for locally advanced non–small-cell lung cancer.
Adherence to antiemetic regimens for patients undergoing emetogenic cancer chemotherapy is poor, according to an online survey of oncology nurses in the United States.
This video examines results of a study that looked at treatment tolerability in elderly patients with HPV-positive oropharyngeal squamous cell carcinoma.
A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.
Quality of life was not improved with the use of early palliative care for patients recently diagnosed with malignant pleural mesothelioma, according to data presented at the World Conference on Lung Cancer.
Adding ginger extract capsules to a standard prophylactic antiemetic did not improve chemotherapy-induced nausea and vomiting in patients undergoing high-dose cisplatin chemotherapy.
This article includes a succinct review of current research into exercise in the cancer setting and a discussion of the American College of Sports Medicine exercise recommendations for cancer survivors. Common acute, long-term, and late effects of cancer and its treatment are also described in the context of ways in which these side effects impact the ability to exercise.
Through this vital new partnership, the Society for Integrative Oncology and ONCOLOGY seek to make integrative medicine part of standard clinical oncology practice, and to help physicians and patients make informed decisions about complementary and alternative medicine to maximize benefits and minimize harms.
In this interview we discuss health disparities in cancer care, how redesigning cancer clinical trials can address some of these disparities, and goals for the “next generation” of cancer health disparities research.
Serial PSA testing with early salvage radiotherapy is a viable option in most high-risk men.
The data for adjuvant radiotherapy remain strong.
This video examines changes in insurance status after implementation of the Affordable Care Act among cancer patients who received radiation therapy.
Women who take multivitamin supplements before their breast cancer diagnosis and during chemotherapy appear to be less likely to develop the debilitating, often long-lasting symptoms of chemotherapy-induced peripheral neuropathy, according to a new study.
From 1989 to 2015, breast cancer death rates decreased by 39%, according to findings from a report from the American Cancer Society. This decrease translates to well over a quarter of a million averted breast cancer deaths in the United States.
This video highlights 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.
This video reviews long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared stereotactic body radiation therapy delivered in one fraction vs four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.
Long-term use of the long-acting insulin analog glargine is associated with an increased risk of breast cancer in women with type 2 diabetes, according to a new population-based cohort study.
Use of unilateral intensity-modulated radiotherapy reduced acute toxicities and maintained oncologic outcomes compared with bilateral IMRT in patients with lateralized palatine tonsillar cancer, according to the results of a new study.
A high rate of cancer patients reported using legalized cannabis, according to the results of a survey conducted at an NCI-designated cancer center in Washington State, which has legalized the medicinal and recreational use of cannabis.
This video highlights studies on HPV-positive head and neck cancer presented at the 2017 ASTRO Annual Meeting.
The FDA has granted accelerated approval to nivolumab (Opdivo) for the treatment of patients with hepatocellular carcinoma who have previously received sorafenib.
Patients who reported severe distress were more likely to miss radiation therapy appointments and be hospitalized during the course of their therapy compared with patients with lower distress scores, according to the results of a study presented at the ASTRO Annual Meeting in San Diego.
Undergoing SBRT prior to starting maintenance chemotherapy significantly improved progression-free survival in patients with limited metastatic non–small-cell lung cancer, according to the results of a phase II study presented at the ASTRO Annual Meeting.
A substantially higher number of nonelderly patients with newly diagnosed cancer had insurance after implementation of the Affordable Care Act, according to the results of a new study.
The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.
An analysis that corrected for differences in implementation found that the two main trials of prostate cancer screening in Europe and the United States both show a reduction in prostate cancer mortality with screening.
The FDA has approved the first gene therapy available in the United States, tisagenlecleucel (Kymriah), for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.